DNA
Ginkgo Bioworks Holdings, Inc.·Healthcare
8.71
0.230%(+0.02)
Close PriceLast Updated: — ET
52W L: $5.3752W H: $17.58
DNA NEWS
prnewswire.com
1d ago
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification BOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™ , a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio . ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management.
prnewswire.com
6d ago
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate ApolloBio's new clinical results further highlight the potential of INOVIO's DNA medicine platform to treat diseases caused by infection with various strains of the human papillomavirus (HPV), eliminating or reducing the need for surgical interventions PLYMOUTH MEETING, Pa., May 21, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its partner for VGX-3100 in China, ApolloBio, announced positive topline results from its pivotal Phase 3 trial of VGX-3100, INOVIO's investigational DNA immunotherapy being developed as a potential treatment for cervical dysplasia.
newsfilecorp.com
May 20
DNA X, Inc. Reports First Quarter 2026 Financial Results
Closed sale of the Company's mobile device assets to NEXA in January 2026 Completed the transfer of the operations of the phone and hotspot business to NEXA Focused on enhancing the DNA X trading platform to prepare the platform for its initial growth phase San Diego, California--(Newsfile Corp. - May 20, 2026) - DNA X, Inc. (NASDAQ: SONM), a provider of cryptocurrency trading services, today announced its financial results for the first quarter ended March 31, 2026. The company operates the DNA X AI trading platform business, and expects to launch an enhanced version to the public later this year.
prnewswire.com
May 19
DNA Finland Extends Fiber-Grade Connectivity to Lower-Density MDUs with Harmonic
Harmonic's SeaStar Optical Node Enables Cost-Effective Broadband Service Expansion in Previously Underserved Brownfield MDU Environments SAN JOSE, Calif., May 19, 2026 /PRNewswire/ -- Harmonic (NASDAQ: HLIT) today announced that DNA Finland, the second largest mobile and fixed broadband operator serving the Finnish market, is expanding multi-gigabit services into lower-density multi-dwelling units (MDUs) with Harmonic's SeaStar™ optical node.
seekingalpha.com
May 13
Ginkgo Bioworks: Another Lost Year
Ginkgo Bioworks (DNA) reported Q1 revenues of $19.5M, down nearly 50% year-over-year and badly missing street estimates even after Biosecurity adjustments. Management is pivoting to autonomous labs but refuses to provide revenue guidance, causing analyst estimates to fall further. DNA continues to burn significant cash, with Q1 cash burn at $49M and 2026 guidance of $125M–$150M, leaving $373M in cash and no debt but weakening flexibility.
gurufocus.com
May 12
The $59B Quiet Shift Reshaping How Patients Access Care
The $59B Quiet Shift Reshaping How Patients Access Care PR Newswire VANCOUVER, BC, May 12, 2026
